FONT-SIZE Plus   Neg

Eli Lilly Says FDA Approved Alzheimer's Diagnostic Agent Amyvid

Eli Lilly and Company (LLY) on Friday said the Food and Drug Administration (FDA) has approved Amyvid, a radioactive diagnostic agent for use in patients being evaluated for Alzheimer's Disease and other causes of cognitive decline.

Amyvid or florbetapir F 18 injection is a molecular imaging agent under investigation for the Positron Emission Tomography imaging of beta-amyloid plaque in the brains of Alzheimer's disease patients.

A negative Amyvid scan indicates sparse-to-no amyloid plaques are present, which is inconsistent with a neuropathological diagnosis of Alzheimer's Disease and reduces the likelihood that a patient's cognitive impairment is due to Alzheimer's Disease.

A positive scan indicates moderate to frequent amyloid plaques are present. This amount of amyloid plaque is present in patients with Alzheimer's Disease, but may also be present in patients with other types of neurologic conditions and in older people with normal cognition.

Amyvid was a lead candidate of Avid Radiopharmaceuticals, which became a wholly owned subsidiary of Lilly through its acquisition by the Indianapolis, Indiana-based health care giant in December 2010.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Large U.S. companies are holding trillions of dollars overseas in an effort to avoid U.S. taxes, with big-name firms like Apple (AAPL), Pfizer (PFE) and PepsiCo (PEP) named as notable examples. This is the claim made by a pair of non-profit groups, who released a study based on the firms' financial statements. Software maker Adobe Systems Inc. (ADBE) Tuesday detailed an outlook for the full year 2016 indicated to miss Wall Street estimates, sending its shares down 8 percent in after-hours trading. Adobe expects full-year 2016 revenues of about $5.7 billion and an adjusted earnings of $2.70 per share. Analysts... Enterprise software maker Adobe (ADBE) provided updated guidance on Tuesday, predicting strong growth over the next three years by giving 2016 projections that are below what market analysts are currently expecting.
comments powered by Disqus
Follow RTT